New Delhi: Drug firm Claris Lifesciences has received approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) for its newly commissioned plant in Ahmedabad.
"This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for Plant 2," Claris Lifesciences said in a filing to the BSE.
This approval is for products presented in glass ampoules manufactured in line 1 of Plant 2, it added.
"This will help in enhancing capacities to grow in regulated markets, especially the European Union. The company's specialty injectables business saw a growth of 30 per cent in the last quarter," the pharmaceutical company said.
The company's Plant 1 is already approved by the UK health regulator, it added.
Ahmedabad-based Claris Lifesciences is a sterile injectables pharmaceutical company with a market presence across 100 countries worldwide.
As of 3:01 p.m.,, shares in Claris Lifesciences were trading at Rs 182.00 apiece on the BSE, up 3.79 per cent from the previous close.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
